Skip to content
Screener

Celldex Therapeutics CLDX Shares (Diluted)

Shares (Diluted) at other companies

Eli Lilly logo
Eli LillyLLY
893.7M-0.7%
Pfizer logo
PfizerPFE
5.7B-0.1%
Rogers Corporation logo
Rogers CorporationROG
18M-2.2%
Amgen logo
AmgenAMGN
544M+0.6%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
106M-2.4%
Incyte logo
IncyteINCY
208.2M+4.8%

Other financials

Income statement

See full
Revenue$22.0K-97.0%
Operating income-$80.6M-26.3%
Net income-$73.5M-29.9%
EPS (diluted)-$0.94-10.6%

Balance sheet

See full
Cash & equivalents$47.5M+106%
Total debt$4.9M+61.8%
Total equity$714.6M+9.0%
Total assets$782.3M+13.0%

Cash flow

See full
Operating cash flow-$57.4M-30.5%
CapEx$3.2M+337%
Free cash flow-$60.6M-35.4%

Valuation

See full
Market cap$3.26B+129%
Enterprise value$3.22B+129%
P/S20,646.4×+20,401×

Profitability

See full
Operating margin-206,220.3%-210,440pp
Net margin-190,220.9%-193,797pp
FCF margin-153,231%-156,630pp

Returns & leverage

See full
Return on equity-43.9%+70.0pp
Debt / equity0.0×
Current ratio11.8×-7.8×

Where this comes from

Reported directly by Celldex Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.

The source filing: Celldex Therapeutics’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001104659-26-091984
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Investment and other income, net7,1207,25712,87016,201
Net loss$(73,503)$(56,600)$(152,188)$(110,396)
Basic and diluted net loss per common share$(0.94)$(0.85)$(2.11)$(1.66)
Shares used in calculating basic and diluted net loss per share77,84066,39272,23466,388
Comprehensive loss:
Net loss$(73,503)$(56,600)$(152,188)$(110,396)
Other comprehensive (loss) income:
Unrealized (loss) gain on marketable securities(1,224)(229)(2,328)25

Item 1. Unaudited Financial Statements

FAQ

What is Celldex Therapeutics's shares (diluted)?
Celldex Therapeutics (CLDX) reported shares (diluted) of 77.8M in Q2 2026.
How has Celldex Therapeutics's shares (diluted) changed year-over-year?
Celldex Therapeutics's shares (diluted) increased by 17.2% year-over-year, from 66.4M to 77.8M.
What is the long-term trend for Celldex Therapeutics's shares (diluted)?
Over 4 years (2021 to 2025), Celldex Therapeutics's shares (diluted) has grown at a 12.2% compound annual growth rate (CAGR), from 167.6M to 265.6M.
What does shares (diluted) mean?
The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.

Ask your AI about Celldex Therapeutics's shares (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude